Replies to post #166750 on Biotech Values

[jq1234]

ABBV/ENTA AASLD Presentation:

Sunday Nov. 3:


5:15 PM - 5:30 PM

75. Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naïve Patients and Prior Null Responders
Eric Lawitz; Christophe Hezode; Peter Varunok; Paul J. Thuluvath; Tolga Baykal; Mudra Kapoor; Sandra S. Lovell; Tianli Wang; Tami Pilot-Matias; Regis A. Vilchez; Barry Bernstein


Posters:


8:00 AM - 5:30 PM

1089. Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 with SVR24 After Treatment with ABT-450/r, ABT-267, ABT-333 + Ribavirin in Patients with Chronic HCV Genotype 1 Infection in the AVIATOR Study
Fred Poordad; Kosh Agarwal; Ziad Younes; Daniel E. Cohen; Wangang Xie; Thomas Podsadecki


8:00 AM - 5:30 PM

1118. Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects with Ribavirin Dose Reductions
Daniel E. Cohen; Wangang Xie; Lois Larsen; Christal Marincic; Mary Knauss-Townsend; Amit Khatri; Thomas Podsadecki; Barry Bernstein